Haichuang Pharmaceutical (688302.SH) released its 2023 annual report. The company did not achieve operating income during the reporting period; net loss attributable to shareholders of listed companies was 294 million yuan, narrowing the year-on-year loss; net loss attributable to shareholders of listed companies was deducted by 325 million yuan in non-recurring profit and loss, which narrowed year-on-year loss; basic loss per share was 2.97 yuan/share.
海创药业(688302.SH)发2023年度业绩，未实现营收，净亏损2.94亿元
Haichuang Pharmaceutical (688302.SH) reported 2023 annual results, unrealized revenue, net loss of 294 million yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.